[ Inglés] What’s the Follow-Up Plan After a Clinical Trial?

Published on

Topics include: Clinical Trials

Patient Power community member Katie wants to know more about how a cancer patient’s health is monitored after participating in a clinical trial. During this Clinical Trial MythBusters segment, Mel Mann, a chronic myeloid leukemia (CML) patient and the longest living #Gleevec survivor, and noted clinical trials expert Dr. Richard Schilsky, from the American Society of Clinical Oncology, discuss doctors’ visits, testing and long-term coverage of trial medicines. Watch now to hear both patient and expert perspectives on post-trial follow-up care.

This is a Patient Empowerment Network program produced by Patient Power. We thank AbbVie, Inc., Astellas, Celgene Corporation, and Novartis for their support.

View more programs featuring , and

Produced in association with


Typically the drugs continue to be provided for free for as long as the patient continues to benefit. Now, sometimes if the drug ultimately gets FDA approved, then it may be necessary at some time in the future for a patient to switch over from the research drug to the commercial drug, but of course at that time the drug is FDA approved. And if the person has insurance, it will generally be covered by their insurance.  

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Related Programs

Why Are Minorities Often Underrepresented in Clinical Trials?

How can ethnic minorities gain access to more clinical trials? Watch as clinical trial experts Dr. Richard Schilsky and Cecelia Mann share their perspectives.


Addressing a History of Fears About Clinical Trials: An Expert Weighs In

How are cancer patients cared for in clinical studies? Tune in to hear expert Dr. Richard Schilsky explain patient consent and safety, clinical trial regulation and more.


Actionable Advice and Resources for Knocking Down Obstacles to Trial Participation

More often than not, only a small fraction of patients enroll in a trial due to barriers posed by financial logistics, distrust and travel, to name a few. How do we remove obstacles, clearing the way for patients to have more access to clinical trials? Watch now to find out.


How Can Experts Overcome Language and Cultural Barriers to Increase Clinical Trial Participation?

How are researchers helping to improve participation by minorities in clinical trials? Watch as expert Dr. Richard Schilsky discusses language and cultural barriers.


Únete a Nuestra Comunidad Regístrate para Eventos Lee Nuestro Último Post

Page last updated on September 10, 2019